MNKD Quote, Financials, Valuation and Earnings

Oragenics has a net margin of 9.67% compared to MannKind's net margin of --. MannKind's return on equity of -- beat Oragenics's return on equity of --.

MannKind has a consensus price target of $10.00, signalling upside risk potential of 92.31%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 257.14%. Given that Oragenics has higher upside potential than MannKind, analysts believe Oragenics is more attractive than MannKind.

MannKind has a beta of 1.266, which suggesting that the stock is 26.58% more volatile than S&P 500. In comparison Oragenics has a beta of 0.847, suggesting its less volatile than the S&P 500 by 15.305%.

MannKind has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MannKind pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

MannKind quarterly revenues are $76.8M, which are larger than Oragenics quarterly revenues of --. MannKind's net income of $7.4M is higher than Oragenics's net income of -$2.5M. Notably, MannKind's price-to-earnings ratio is 52.00x while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MannKind is 5.34x versus 1.10x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of 9.67% compared to MannKind's net margin of -2357.27%. MannKind's return on equity of -- beat Palatin Technologies's return on equity of --.

MannKind has a consensus price target of $10.00, signalling upside risk potential of 92.31%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 785.18%. Given that Palatin Technologies has higher upside potential than MannKind, analysts believe Palatin Technologies is more attractive than MannKind.

MannKind has a beta of 1.266, which suggesting that the stock is 26.58% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.66%.

MannKind has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MannKind pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

MannKind quarterly revenues are $76.8M, which are larger than Palatin Technologies quarterly revenues of $350K. MannKind's net income of $7.4M is higher than Palatin Technologies's net income of -$2.4M. Notably, MannKind's price-to-earnings ratio is 52.00x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MannKind is 5.34x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Rhythm Pharmaceuticals has a net margin of 9.67% compared to MannKind's net margin of -103.5%. MannKind's return on equity of -- beat Rhythm Pharmaceuticals's return on equity of -178.94%.

MannKind has a consensus price target of $10.00, signalling upside risk potential of 92.31%. On the other hand Rhythm Pharmaceuticals has an analysts' consensus of $75.08 which suggests that it could grow by 47.31%. Given that MannKind has higher upside potential than Rhythm Pharmaceuticals, analysts believe MannKind is more attractive than Rhythm Pharmaceuticals.

MannKind has a beta of 1.266, which suggesting that the stock is 26.58% more volatile than S&P 500. In comparison Rhythm Pharmaceuticals has a beta of 2.300, suggesting its more volatile than the S&P 500 by 130.019%.

MannKind has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MannKind pays -- of its earnings as a dividend. Rhythm Pharmaceuticals pays out -- of its earnings as a dividend.

MannKind quarterly revenues are $76.8M, which are larger than Rhythm Pharmaceuticals quarterly revenues of $41.8M. MannKind's net income of $7.4M is higher than Rhythm Pharmaceuticals's net income of -$43.3M. Notably, MannKind's price-to-earnings ratio is 52.00x while Rhythm Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MannKind is 5.34x versus 23.89x for Rhythm Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of 9.67% compared to MannKind's net margin of --. MannKind's return on equity of -- beat Theriva Biologics's return on equity of --.

MannKind has a consensus price target of $10.00, signalling upside risk potential of 92.31%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 419.93%. Given that Theriva Biologics has higher upside potential than MannKind, analysts believe Theriva Biologics is more attractive than MannKind.

MannKind has a beta of 1.266, which suggesting that the stock is 26.58% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.159, suggesting its more volatile than the S&P 500 by 15.945%.

MannKind has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MannKind pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

MannKind quarterly revenues are $76.8M, which are larger than Theriva Biologics quarterly revenues of --. MannKind's net income of $7.4M is higher than Theriva Biologics's net income of -$4.4M. Notably, MannKind's price-to-earnings ratio is 52.00x while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MannKind is 5.34x versus 1.59x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.